Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_01040 |
| Species: | Homo sapiens |
| Position : | chr14:36356112-36635984 |
| Year: | 2025 |
| Title: | Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Disease |
| Disease Name: | skin melanoma |
| PMID: | 39677680 |
| MONDO: | MONDO:0005105 |
| Tissue: | Skin |
| Tissue Ontology ID: | UBERON:0000014 |
| Cell Source: | COLO829 |
| CVCL ID: | CVCL_1137 |
| Cell Type: | melanoma cell |
| Cell Ontology ID: | CL:0002573 |
| Experiment Type: | Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | Hi-C, ChIP-seq, RNA-seq |
| Low Throughput Method: | CRISPR Knockout, qRT-PCR, Western blot |
| Target gene : | NKX2-1 |
| TF name : | FOXA2 |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| FOXA2 | FOXA1 transcription factor network | pid | 45 |
| FOXA2 | FOXA2 and FOXA3 transcription factor networks | pid | 45 |
| FOXA2 | Hedgehog signaling events mediated by Gli proteins | pid | 49 |
| FOXA2 | Regulation of gene expression in beta cells | reactome | 17 |
| FOXA2 | Maturity onset diabetes of the young | kegg | 25 |
| FOXA2 | Hs_Endoderm_Differentiation_WP2853_88152 | wikipathways | 62 |
| FOXA2 | Hs_Dopaminergic_Neurogenesis_WP2855_87239 | wikipathways | 19 |
| FOXA2 | Hs_Heart_Development_WP1591_90186 | wikipathways | 28 |
| FOXA2 | Hs_Ectoderm_Differentiation_WP2858_89329 | wikipathways | 56 |